None of the four law firms publicly concerned (so far) over LabCorp’s purchase of Covance seem to share my worry about whether LabCorp is just an about-to-burst high-flying balloon of unsustainable growth (with the signs being LH officers’ use of parachutes via significant sale of their shares, and news articles concerning extraneous accounting). And it’s hardly likely that any of the four firms give a damn that LabCorp purchased Orchid Cellmark under a cloud of perhaps mishandling the DNA testing of evidence, even though it’s another sign that LabCorp may be more monkey business than actual business. Here are the four firms:
- Brower Piven, A Professional Corporation – http://www.marketwatch.com/story/shareholder-alert-brower-piven-launches-an-investigation-into-the-proposed-sale-of-covance-inc-and-encourages-investors-to-contact-the-firm-for-additional-information-2014-11-03?reflink=MW_news_stmp
- Harwood Feffer LLP – http://money.cnn.com/news/newsfeeds/articles/prnewswire/DC55848.htm
- Pomerantz LLP – http://money.cnn.com/news/newsfeeds/articles/prnewswire/DC57050.htm
- Brodsky & Smith, LLC – http://money.cnn.com/news/newsfeeds/articles/prnewswire/DC56021.htm
Here’s one of my old posts concerning LabCorp:
Orchid Cellmark/LabCorp deal still pending, so hey, FTA, is that all you have to say?
[Update: Now at least six law firms are concerned about LabCorp’s purchase of Covance: Rigrodsky & Long, P.A., has joined the others – http://www.marketwatch.com/story/covance-inc-shareholder-alert-rigrodsky-long-pa-announces-investigation-of-buyout-2014-11-05-12159510 – and so has Levi & Korsinsky, LLP – http://news.gnom.es/pr/cvd-investor-alert-levi-korsinsky-llp-launches-investigation-of-the-board-of-directors-of-covance-inc-regarding-the-fairness-of-the-sale-of]